Sudden death and acute myocardial infarction account for almost 50% of the first clinical manifestations of coronary artery disease.
1,2 Many of these events are attributed to the sudden destabilization of vulnerable plaques in vulnerable patients. The challenge is to find a reliable tool, which will enable interventional cardiologists to detect these events prior to their occurrence. Such an attempt is detailed in a small study (275 patients) published in this issue demonstrating that utilizing near-infrared spectroscopy (NIRS) can predict late cardiovascular events. Although the results are intriguing, the study can be criticized because it pulls together two randomized trials with different background therapy and endpoints, and lacks a detailed plaque-level analysis. Still, it reports the largest study population and the longest follow-up using NIRS to identify patients with known coronary artery disease (CAD) at risk of new events. 3 One can conclude that having cholesterol in the wall of the artery is a marker for future cardiovascular events, such as myocardial infarction and new unplanned revascularization. These adverse events increase 19% for every 100 unit increase in the maximum lipid core burden index (MaxLCBI) of the worst 4 mm lesion. The same trend is seen if you consider the worst 10 mm or the entire studied segment. The study demonstrates clinical significance with regards to the magnitude of escalation of events, with LCBI levels moving from <5% of events for the lowest quartile (MaxLCBI 4 mm: 0-83) to >20% for the highest quartile (MaxLCBI 4 mm: > _360). These results are sufficient to reconsider the current standardized strategy of secondary prevention, which was followed but proved to be obviously insufficient and in need of individualized improvements in this high-risk group. Multivariate analysis taking into consideration clinical and angiographic variables and plaque volume measured with intravascular ultrasound (IVUS) confirmed that plaque cholesterol assessed with NIRS was an independent predictor of events and could not be substituted by other clinical, angiographical, IVUS, or procedural parameters. MaxLCBI became an even more powerful predictor if events related to the target lesion treated were excluded. Further, the LCBI levels were not limited to predicting only events related to the arteries studied with NIRS but also to events related to other coronary vessels and, albeit with low numbers, to other vascular locations. Having persistent lipid deposits appears to be a systemic marker of plaque instability and progression. The biggest drawback of this invasive approach as a screening tool is its limitation to secondary prevention for patients in need of a coronary angiogram, a test performed anyway in hundred of thousands of patients per year in Europe alone following acute coronary syndromes or for poorly controlled angina symptoms. 4 The ideal screening tool also applicable to primary prevention should be non-invasive. Despite advances in non-invasive imaging and provocative tests, there are still many patients without critical coronary stenoses undergoing coronary angiography to rule out ischaemia as the potential cause of symptoms. Multidetector computed tomography (MDCT) imaging could be an alternative to invasive investigations since its negative predictive value is very high. 5 In other patients, however, especially when MDCT is carried out with 'questionable' indications and in older patients, MDCT angiography may trigger unnecessary angiograms showing no critical stenoses. We should avoid wasting this great opportunity to define more precisely their risk, using invasive imaging including NIRS-IVUS in order to single out the patients who need more active treatment and follow-up from the majority that can simply be reassured and started on conventional secondary prevention regimens. Plaque volume is known to have a negative impact on prognosis 6, 7 and is widely used to investigate the effects of therapy and lifestyle changes on plaque progression and regression. ). The powerful and expensive injectable proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab reduced LDL cholesterol to nearly one-third of the level measured in the control patients treated with the maximally tolerated doses of statins (and/or ezitimibe). This study shows that the predictive power of MaxLCBI 4 mm for all-cause and cardiac mortality in combination with myocardial infarction and unplanned revascularization is greater than the power shown for plaque volume, 11 the variable studied in the GLAGOV Trial, 12 the mechanistic IVUS study of evolocumab, showing a marginal reduction of plaque volume at 0.91% at 18 months. In the FOURIER trial, 13 it will take an entire year to start seeing a divergence of the Kaplan-Meier curves, with an overall small absolute difference of 2% at 3 years. Differences in patient characteristics (for instance 42% of the patients in this NIRS study had acute coronary syndrome vs. none of the FOURIER patients) may explain this finding, but the 20% change at 1 year between the lowest and highest quartile of MaxLCBI 4 mm suggests that this index is a better parameter of vulnerability than overall plaque volume and may become the future gold standard in trials of atherosclerosis stabilization.
It looks like we may have an amber light switching on to warn us when our patients are prone to crash on the roads of life. Let us stop them without waiting for the red signal of symptoms when it might be too late. We certainly need more than a retrospective substudy of >300 patients. The largest study in the field is the Lipid Rich Plaque (LRP) trial, a 1563 patient trial due to complete follow-up in the next months and report results in 2018 (ClinicalTrials.gov Identifier: NCT02033694). The patient characteristics in the LRP trial presenting with acute coronary syndrome are similar to those of this study. In the LRP study any MaxLCBI at 4 mm >250 was compared with LCBI <250. Patients are followed for 2 years to address specifically the vulnerable patient hypothesis as in the current study. The LRP study also addresses the vulnerable plaque hypothesis as to whether the event was specifically related to the lesion with high LCBI, and will explore what is the threshold of LCBI to predict an event. The results of the present study are encouraging and build up expectations for the LRP study.
Having a predictive index may be a good first step to reduce future events, but is it good enough to save life? It is upon us to identify and apply life-saving therapies and interventions. Candidate treatments include new drugs (besides PCSK9 inhibitors, HDL agonists, empagliflozin, etc.), invasive non-cardiac treatments such as bariatric surgery or apheresis, and coronary interventions such as implantation of biodegradable scaffolds for focal high-risk lesions, a strategy already under investigation following the results of NIRS-IVUS in the pilot PROSPECT 2 randomized trial (ClinicalTrials.gov Identifier: NCT02316886). Invasive imaging can help to apply more precision medicine and to select therapies for the correct candidates or to avoid an expensive and/or unpleasant intervention in those who will not benefit. Today we are far from having an easy and reliable screening test which could be applicable in large population studies and can be used to eradicate acute coronary events, but this test is a promising start to detecting future coming events for the highest risk cohorts.
